Navigation Links
Oramed Patent Granted in India for Oral Administration of Proteins
Date:3/29/2016

JERUSALEM, March 29, 2016 /PRNewswire/ --

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that the Company's patent for its invention, titled "Methods and Compositions for Oral Administrations of Proteins" has been granted by the Indian Patent Office.

About Oramed Pharmaceuticals 

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, Oramed's Protein Oral Delivery (PODTM) technology is based on over 30 years of research by top scientists at Jerusalem's Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801). Having completed multiple Phase IIa trials, the Company's Phase IIb trial on type 2 diabetes is ongoing under an Investigational New Drug application with the U.S. Food and Drug Administration. In addition Oramed is developing an oral GLP-1 analog capsule (ORMD-0901).

For more information, the content of which is not part of this press release, please visit http://www.oramed.com

Forward-looking statements: This press release contains forward-looking statements. For example, we are using forward-looking statements when we discuss that ORMD-0801 has the potential to create a new paradigm in the treatment of diabetes, potentially slowing disease progression and delaying or even eliminating late-stage complications, that orally administered insulin should bring with it enhanced patient compliance or when we discuss our clinical trials and revolutionizing the treatment of diabetes with our products.  These forward-looking statements are based on the current expectations of the management of Oramed only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for our product candidates; competition from other pharmaceutical or biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; laboratory results that do not translate to equally good results in real settings; our patents may not be sufficient; and final that products may harm recipients, all of which could cause the actual results or performance of Oramed to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Oramed undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Oramed, reference is made to Oramed's reports filed from time to time with the SEC.

Company Contact
Oramed Pharmaceuticals
Ariella Vaystooch
Office: +972-2-566-0001 ext. 2
US: +1-718-831-2512 ext. 2
Email: ariella@oramed.com


'/>"/>
SOURCE Oramed Pharmaceuticals Inc.
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. Oramed Pharmaceuticals Shareholder Letter
2. Oramed Announces Closing of Licensing and Investment Deal with HTIT for Oral Insulin Capsule in China
3. Oramed Signs up to $50 Million Licensing and Investment Agreements for Oral Insulin Capsule in China
4. Oramed Patent Allowed in the US for Oral Administration of Proteins
5. Oramed Completes Randomization of Over 50% of Patients in Phase IIb Oral Insulin Study
6. Oramed to Present at the Rodman & Renshaw Global Investment Conference
7. Sinopharm Capital-Hefei Signs Letter of Intent with Oramed for $50,000,000 Investment and Licensing Deal in China
8. Oramed Enrolls First Patient in its Phase IIb Oral Insulin Study
9. Oramed Granted Patent in Russia for Oral Administration of GLP-1
10. Oramed Announces Closing of $5.36 Million Registered Direct Offering
11. Oramed to Raise $5.36 Million in Registered Direct Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2020)... ... , ... May is Talking is Power Month, a national effort to spark ... The focus of Power to Decide’s #TalkingIsPower campaign reminds parents, trusted adults and other ... Mackenzie Piper, MPH, CHES, provides five strategies parents, trusted adults and other champions can ...
(Date:5/28/2020)... Tenn. (PRWEB) , ... May 28, 2020 , ... ... care continuum, The Beryl Institute releases its latest white paper, Caring for our ... evidence of successful patient experience practices in pediatric settings and highlights key findings ...
(Date:5/27/2020)... ... ... in April 2020: , CARDIOLOGY, Passaic County, Dr. Anuj Shah ... Jo , Dr. Mi Jo , Morris County, ... , FAMILY PRACTICE, Camden County, Dr. Krista King ...
Breaking Medicine Technology:
(Date:5/26/2020)... ... May 26, 2020 , ... As much of ... the United States are joining forces to start a country-wide movement of physical ... to save lives. #FitForTheFrontLine is a national fitness challenge beginning Tuesday, May 26 ...
(Date:5/21/2020)... ... May 21, 2020 , ... Summit Medical , ... deliver over one million FDA-compliant face shields — designed, engineered and manufactured in ... critical need for personal protective equipment (PPE) for both front-line health care workers ...
(Date:5/21/2020)... (PRWEB) , ... May 21, 2020 , ... Friends of ... 35, has been endorsed by Planned Parenthood Southeast Advocates (PPSEA). PPSEA ... support family planning and the full range of reproductive health care. PPSEA educates and ...
(Date:5/21/2020)... ... May 21, 2020 , ... Casenet® LLC today released TruCare ... care management and utilization management at health insurance plans. Developed over two years ... significant usability and automation upgrades to all of its existing features, introduces more ...
(Date:5/16/2020)... ... May 15, 2020 , ... For patients who have gone to see Andy Gaertner, D.M.D ... has always had in place. After being allowed to re-open during the current pandemic, they ... staff are as safe and comfortable as possible while going through their dental exams and ...
Breaking Medicine News(10 mins):